[2Firsts, September 19, 2025, Dortmund] At the world’s largest tobacco industry event—the InterTabac International Tobacco Exhibition in Dortmund, Germany—Heno Biotech officially released its 2024 Environmental, Social, and Governance (ESG) Report. This marks the company’s third consecutive annual ESG disclosure since 2023, systematically presenting its practices and achievements in environmental protection, social responsibility, and corporate governance.
As a leading enterprise in natural nicotine extraction in China, Heno Biotech chose this global industry platform to release its ESG report. The move not only reflects the company’s long-term commitment to sustainable development but also delivers a clear signal of corporate responsibility and internationalization. The release drew wide attention, with partners, industry representatives, and visitors recognizing Heno Biotech’s ESG commitments.
Multi-Dimensional Achievements in Sustainable Development
Heno Biotech’s 2024 ESG Report is structured around the three pillars of “Environment, Social, and Governance,” highlighting the following accomplishments:
Green Ecological Practices
- GHG Reduction Target: The company pledged to use 2024 as a baseline and achieve an average annual reduction of 8% in greenhouse gas emissions intensity by 2027.
- Clean Energy and Circular Economy: Rooftop and parking-lot photovoltaic projects are underway, with a planned installed capacity of 450 kWp by 2025. Energy efficiency has been further enhanced through waste heat recovery and an energy monitoring system.
- Emission Management: In 2024, the company ensured compliant discharge of waste gas and wastewater. Through process optimization, it reduced solvent oil consumption per unit by 2.04%, reflecting synergy between green development and cost control.
Technological Innovation and Product Quality
- The report shows that Heno Biotech currently holds 94 intellectual property achievements.
- In 2024, the company filed 6 new invention patents and 4 utility model patents, while being granted 4 invention patents and 2 utility model patents by the National Intellectual Property Administration.
- Heno Biotech’s high-purity natural nicotine products reached 99.9% purity, significantly above the national standard (≥99%), and are trusted by global customers as premium raw materials.
Compliance Governance System
- Heno Biotech obtained certification for ISO 37301 Compliance Management System and ISO 45001 Occupational Health and Safety Management System, underscoring the systematic and internationalized nature of its governance.
- The report disclosed that in 2024, the company reviewed 327 contracts, with 14.7% rejected or withdrawn due to compliance risks, effectively preventing operational risks. There were zero incidents of bribery, unfair competition, or information leaks throughout the year.
Employee Care and Social Responsibility
- Employee contract signing rate remained at 100%, with strict implementation of anti-discrimination and labor protection policies.
- Among the highest level of management, 45% were from minority or vulnerable groups, reflecting Heno’s commitment to diversity and inclusion.
- Employee satisfaction surveys showed 96% of staff expressed strong confidence in company management and future development.
- In community engagement, the company actively participated in local initiatives, sponsoring the “EnBA” basketball tournament and donating to charitable causes, integrating business growth with social value creation.
Management Message: Responsibility Drives Future Vision
At the release event, a Heno Biotech representative stated:
“ESG is more than just a report—it is the foundation of Heno Biotech’s development. We remain steadfast in our commitment to green development, compliance governance, and social responsibility, embedding sustainability goals into both our corporate strategy and daily operations. Amid industry transformation and intensifying global competition, Heno Biotech will continue to be innovation-driven and responsibility-oriented, striving to be a global leader in natural nicotine and its applications.
Looking ahead, we aim not only to consolidate our leading position in China but also to demonstrate the sustainable strength of Chinese enterprises in international markets. We seek to work hand in hand with global partners to build responsible supply chains and jointly drive the industry’s green transition and long-term healthy growth.”
This message not only set the tone for the report’s release but also conveyed Heno Biotech’s firm belief in responsibility as the driving force for its international development path.
About Heno Biotech
Founded in 2011 and headquartered in Enshi, Hubei, Heno Biotech has long specialized in the production and multi-functional applications of natural nicotine, becoming a leading player in its niche sector in China. The company adheres to green development and innovation-driven strategies, holding 94 intellectual property achievements and earning honors such as “National Intellectual Property Advantage Enterprise” and “National Specialized and Innovative ‘Little Giant’ Enterprise.” Heno’s natural nicotine products, with a purity level of 99.9%, are widely used in pharmaceuticals, vaporization, and next-generation tobacco products.
Contact Information
Website: 湖北和诺生物工程股份有限公司
Email: sales@heno.net.cn
